Cetuximab + Mitomycin C + 5-Fluoruracil
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Cancer in the Anal Region
Conditions
Locally Advanced Cancer in the Anal Region
Trial Timeline
Jun 1, 2012 → Jan 1, 2020
NCT ID
NCT01621217About Cetuximab + Mitomycin C + 5-Fluoruracil
Cetuximab + Mitomycin C + 5-Fluoruracil is a phase 1 stage product being developed by Merck for Locally Advanced Cancer in the Anal Region. The current trial status is completed. This product is registered under clinical trial identifier NCT01621217. Target conditions include Locally Advanced Cancer in the Anal Region.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01621217 | Phase 1 | Completed |
Competing Products
20 competing products in Locally Advanced Cancer in the Anal Region